Profile data is unavailable for this security.
About the company
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
- Revenue in USD (TTM)0.00
- Net income in USD-82.83m
- Incorporated2016
- Employees52.00
- LocationEnliven Therapeutics Inc6200 Lookout RoadBOULDER 80301United StatesUSA
- Phone+1 (720) 647-8519
- Fax+1 (302) 655-5049
- Websitehttps://www.enliventherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 10.78m | -262.59m | 930.84m | 55.00 | -- | 3.66 | -- | 86.32 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Sana Biotechnology Inc | 0.00 | -244.90m | 954.38m | 328.00 | -- | 2.81 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Nuvation Bio Inc | 1.44m | -510.72m | 970.86m | 167.00 | -- | 2.47 | -- | 676.56 | -2.11 | -2.11 | 0.0064 | 2.43 | 0.0023 | -- | 0.4216 | 28,137.26 | -82.63 | -16.27 | -87.18 | -16.65 | 6.13 | -- | -35,590.24 | -- | -- | -- | 0.0214 | -- | -- | -- | 27.25 | -- | -- | -- |
| IGM Biosciences Inc | 2.91m | -220.40m | 987.66m | 204.00 | -- | 8.06 | -- | 339.28 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Cullinan Therapeutics Inc | 0.00 | -142.16m | 998.94m | 85.00 | -- | 1.52 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.01bn | 300.00 | -- | 2.78 | -- | 4.89 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.03bn | 52.00 | -- | 3.37 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Praxis Precision Medicines Inc | 1.77m | -123.74m | 1.05bn | 82.00 | -- | 2.52 | -- | 595.38 | -10.26 | -10.26 | 0.1393 | 23.60 | 0.0062 | -- | -- | 21,597.56 | -43.07 | -74.04 | -46.74 | -85.12 | -- | -- | -6,987.01 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Vir Biotechnology Inc | 78.88m | -483.04m | 1.07bn | 587.00 | -- | 0.7431 | -- | 13.51 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Pharvaris NV | 0.00 | -126.85m | 1.09bn | 82.00 | -- | 2.96 | -- | -- | -2.66 | -2.66 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Travere Therapeutics Inc | 177.64m | -383.45m | 1.10bn | 380.00 | -- | 72.43 | -- | 6.18 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| AnaptysBio Inc | 30.47m | -170.12m | 1.10bn | 117.00 | -- | 101.55 | -- | 36.22 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.11bn | 116.00 | -- | 2.54 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.14bn | 50.00 | -- | 3.87 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.15bn | 452.00 | -- | -- | -- | 115.55 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Enliven Therapeutics Inc's reporting currency: US Dollar USD
48.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 4.93m | 10.44% |
| Commodore Capital LPas of 30 Jun 2024 | 3.97m | 8.41% |
| Fairmount Funds Management LLCas of 30 Jun 2024 | 3.20m | 6.78% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.45m | 5.18% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.31m | 4.89% |
| RA Capital Management LPas of 30 Jun 2024 | 2.12m | 4.49% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.74m | 3.69% |
| Adage Capital Management LPas of 30 Jun 2024 | 840.00k | 1.78% |
| Pictet Asset Management SAas of 30 Jun 2024 | 778.11k | 1.65% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 769.26k | 1.63% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
